Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07600723 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)

StatusNot Yet Recruiting
PhasePhase 4
Started2026-11-04
View on ClinicalTrials.gov ↗

Amendment history

2026-08-05
minor
Study Status v2
Start date2026-07-15→2026-11-04
2026-06-25
minor
Study Status, Contacts/Locations v1
Start date2026-06-24→2026-07-15
2026-05-15
minor
Original filing
401 trials monitored
See 24 trials at risk
1,786 trials monitored
See 77 trials at risk
Researchers are looking for other ways to treat people in India with pulmonary arterial hypertension (PAH), also known as Group 1 pulmonary hypertension (PH). In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow to the lungs. This causes high blood pressure in the lungs and can overwork the heart. PAH can make it hard to breathe and be active. Researchers want to learn if sotatercept, the study medicine, can be given with standard treatment to help treat PAH. The standard treatment (the usual treatment) for PAH includes one or multiple medicines. However, these may not fully work or treat the symptoms of PAH in some people. The goal of this study is to learn about the safety and tolerability of sotatercept when it is given with standard treatment to people in India.
Trial Details
NCT Number NCT07600723
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Pulmonary Arterial Hypertension
Enrollment 30 participants
Start Date 2026-11-04
Primary Completion 2028-04-03 (estimated)
Study Completion 2028-04-03 (estimated)
Updated on ClinicalTrials.gov 2026-08-07